Barrington Research Reaffirms “Outperform” Rating for U.S. Physical Therapy (NYSE:USPH)

Barrington Research reiterated their outperform rating on shares of U.S. Physical Therapy (NYSE:USPH) in a report issued on Wednesday, Benzinga reports. They currently have a $108.00 price target on the stock. Barrington Research also issued estimates for U.S. Physical Therapy’s Q4 2024 earnings at $0.56 EPS, FY2024 earnings at $2.20 EPS, Q1 2025 earnings at $0.43 EPS, Q2 2025 earnings at $0.77 EPS, Q3 2025 earnings at $0.61 EPS, Q4 2025 earnings at $0.69 EPS, FY2025 earnings at $2.50 EPS and FY2026 earnings at $2.85 EPS.

Several other research firms have also weighed in on USPH. Bank of America reaffirmed a neutral rating and issued a $90.00 price objective (down from $114.00) on shares of U.S. Physical Therapy in a research note on Monday, October 7th. StockNews.com raised U.S. Physical Therapy from a sell rating to a hold rating in a research note on Wednesday, August 21st.

U.S. Physical Therapy Stock Up 3.6 %

USPH opened at $80.32 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 75.77, a price-to-earnings-growth ratio of 3.16 and a beta of 1.39. The business has a 50-day moving average of $84.09 and a two-hundred day moving average of $94.40. U.S. Physical Therapy has a 12 month low of $76.18 and a 12 month high of $113.63.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.82 by ($0.09). The business had revenue of $167.19 million during the quarter, compared to analysts’ expectations of $163.34 million. U.S. Physical Therapy had a net margin of 4.06% and a return on equity of 8.18%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.76 EPS. On average, research analysts expect that U.S. Physical Therapy will post 2.47 earnings per share for the current year.

U.S. Physical Therapy Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 23rd were given a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 2.19%. The ex-dividend date was Friday, August 23rd. U.S. Physical Therapy’s dividend payout ratio (DPR) is presently 166.04%.

Insider Buying and Selling

In related news, Director Kathleen A. Gilmartin purchased 2,000 shares of U.S. Physical Therapy stock in a transaction that occurred on Tuesday, September 3rd. The shares were purchased at an average cost of $86.09 per share, with a total value of $172,180.00. Following the transaction, the director now owns 18,904 shares of the company’s stock, valued at approximately $1,627,445.36. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other U.S. Physical Therapy news, COO Graham D. Reeve sold 1,724 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $82.50, for a total value of $142,230.00. Following the transaction, the chief operating officer now directly owns 7,038 shares of the company’s stock, valued at $580,635. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kathleen A. Gilmartin bought 2,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was acquired at an average cost of $86.09 per share, for a total transaction of $172,180.00. Following the completion of the transaction, the director now owns 18,904 shares in the company, valued at $1,627,445.36. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On U.S. Physical Therapy

A number of institutional investors have recently made changes to their positions in the business. Texas Permanent School Fund Corp raised its position in shares of U.S. Physical Therapy by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 13,116 shares of the company’s stock valued at $1,480,000 after purchasing an additional 170 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of U.S. Physical Therapy by 18.6% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,188 shares of the company’s stock valued at $110,000 after purchasing an additional 186 shares in the last quarter. Louisiana State Employees Retirement System raised its position in shares of U.S. Physical Therapy by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,600 shares of the company’s stock valued at $702,000 after purchasing an additional 200 shares in the last quarter. Martin Capital Advisors LLP increased its holdings in shares of U.S. Physical Therapy by 1.6% in the 3rd quarter. Martin Capital Advisors LLP now owns 13,138 shares of the company’s stock valued at $1,112,000 after acquiring an additional 201 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of U.S. Physical Therapy by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 3,002 shares of the company’s stock valued at $339,000 after acquiring an additional 206 shares during the last quarter.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.